These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33909256)

  • 21. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
    Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ;
    Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
    Hanafy AS; Bassiony MA; Basha MAA
    Hepatol Int; 2019 Mar; 13(2):165-172. PubMed ID: 30758786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
    Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
    Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders.
    de Gennaro N; Diella L; Monno L; Angarano G; Milella M; Saracino A
    BMC Infect Dis; 2020 Mar; 20(1):196. PubMed ID: 32138757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].
    Wei JY; Lin DN; Wu ZB; Zhu JY; Zhao ZX; Mei YY; Lin CS; Zhang J; Zhang XH
    Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):933-939. PubMed ID: 30669787
    [No Abstract]   [Full Text] [Related]  

  • 26. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
    Garrison KL; German P; Mogalian E; Mathias A
    Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
    Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
    J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
    Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
    World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens.
    El Kassas M; Alboraie M; Naguib M; Omar H; Tahan AE; Moaz I; Abdellah M; Ezzat S; Wifi MN; Sherief AF; Eltabbakh M; Abdelsalam L; Eissa AH; Omran D
    Turk J Gastroenterol; 2019 Aug; 30(8):708-713. PubMed ID: 31418415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
    Ahmed EI; Abdel Wahed WY; Hassan EA; Ahmed TI
    Curr Drug Saf; 2018; 13(3):187-195. PubMed ID: 30009714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
    Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.
    Youssef NF; El Kassas M; Farag A; Shepherd A
    BMC Gastroenterol; 2017 Jan; 17(1):18. PubMed ID: 28109264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Direct-acting antiviral agents, hepatitis C and dialysis: an update].
    Fabrizi F; Lampertico P; Messa P
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study.
    Ibáñez-Samaniego L; Rapado-Castro M; Cabrero L; Navarrete C; García-Mulas S; Ahumada A; Marquez L; Pérez MD; Rincon D; Bañares R; Garcia-Martinez R
    Eur J Neurol; 2022 Feb; 29(2):400-412. PubMed ID: 34634159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.